|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.03.26 - 12:03
|
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
Phase 2/3 Duravelo-2 pivotal trial evaluating zelenectide pevedotin (zelenectide) plus pembrolizumab in metastatic urothelial cancer (mUC) successfully identifies 6mg/m2 zelenectide two weeks on, one week off dose (6mg dose) as optimal, demonstrating response rates comparable to published rates for standards of care with a differentiated tolerability profile
Bicycle to convert Duravelo-2 to a randomized Phase 2 trial while determining appropriate next steps for the program
Strategic reprioritization to focus on BT5528 and next generation Bicycle® conjugates, including Bicycle® Radioconjugates (BRC®); additional EphA2 human imaging data and Phase 1 BT5528 combination data planned for the first half of 2026
Strategic partnerships established to enable an end-to-end isotope agnostic strategy to support the potential discovery, development and commercial supply of a portfolio of BRCs
Cash and cash equivalents of $628 million as of December 31, 2025, with expected cash runway extended into 2030 following a ...
|
|
|
06.02.26 - 12:15
|
Nukleare Revolution aus UK: Atommüll zur Krebstherapie (Tichys Einblick)
|
|
|
Der Begriff „Atommüll“ ist scheinbar untrennbar verbunden mit höchst negativen Assoziationen. Jahrtausendelang bleibt er eine Gefahr für die Menschheit, und selbst kleine Dosen der von dieser Art Abfall ausgehenden radioaktiven Strahlung können Krebs auslösen. Das Unternehmen Bicycle Therapeutics in der britischen Hochschulstadt Cambridge kehrt den Spieß jetzt um. Es nutzt den vermeintlichen Müll, um Krebs
Der Beitrag Nukleare Revolution aus UK: Atommüll zur Krebstherapie erschien zuerst auf Tichys Einblick....
|
|
|
|
|
03.02.26 - 13:06
|
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline (Business Wire)
|
|
|
Travis Thompson appointed chief financial officer; to succeed Alethia Young
Michael Method, M.D., MPH, MBA promoted to chief medical officer; to succeed Eric Westin, M.D.
Michael Skynner, Ph.D., chief technology officer, transitioning to chief scientific officerCAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of innovation.
Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle's senior vice president and chief accounting officer and previously spent his career at EY in its life sciences practice supporting a broad range of companies of all sizes and stages of development, has been appointed as Bicycle's chief financial officer (CFO). In this role, Mr. Thompson will continue to oversee finance and accounting functions, and now inv...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
